Cellular Zip Codes and Cancer Care: David Loynd on Endurex’s Breakthrough Delivery Platform | Ep. 12

In this episode of Industry Ignited, Dr. Leeanne Aguilar interviews David Loynd, President & CEO of Endurex Pharmaceuticals, on how a peptide-directed nanoparticle drug delivery platform—built around “cellular zip codes”—targets tumors while sparing healthy tissue. Drawing on engineering discipline, systems thinking, and partnerships with institutions like MD Anderson, David explains why traditional chemotherapy’s systemic toxicity falls short and how Endurex localizes payloads to hard-to-treat cancers such as triple-negative breast cancer, ovarian cancer, and glioblastoma. We dive into manufacturing-minded optimization (design of experiments, polymeric nanocarriers), scale-up paths (microfluidics, impinging-jet, or patient-specific small-scale units), and a pipeline that extends beyond chemo to immunotherapies, RNA/antisense cargos, and vaccine delivery. The result: potential for higher efficacy, lower toxicity, improved patient experience, and scalable systems that move from invention to impact. If you’re in biotech, pharma operations, or industrial process design, this conversation is a masterclass in precision delivery, process innovation, and commercialization strategy.